SABS
SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
Latest data update time: Updated on 2026-01-31
Latest data update time: Updated on 2026-01-31
4.26 / 10Overall Score
NeturalInvestment Rating
4.26 / 10Overall Score
NeturalInvestment Rating
Trend Analysis of SABS
- Based on a composite score of 4.26/10, we rate SABS as a Netural. Our analysis breaks down into 2.69/10 for Fundamentals, 4.46/10 for Technicals, and 4.96/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Technical Analysis of SABS?
Is SABS undervalued or overvalued?
Is money flowing into or out of SABS?
Trend Analysis of SABS
- Based on a composite score of 4.26/10, we rate SABS as a Netural. Our analysis breaks down into 2.69/10 for Fundamentals, 4.46/10 for Technicals, and 4.96/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Is SABS undervalued or overvalued?
Technical Analysis of SABS?
Is money flowing into or out of SABS?
